| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/01/2009 | EP1315417B1 Mutant non-human mammal for expressing the alpha6 acetylcholine nicotinic receptor subunit and use for screening substances capable of interacting with said receptor |
| 07/01/2009 | EP1301486B1 Imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 07/01/2009 | EP1248602B1 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| 07/01/2009 | EP1203025B1 Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and beta1 integrins |
| 07/01/2009 | CN101472612A Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof |
| 07/01/2009 | CN101472583A Method of improved diuresis in individuals with impaired renal function |
| 07/01/2009 | CN100506846C Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 07/01/2009 | CN100506845C IFNAR2 mutants, their production and use |
| 07/01/2009 | CN100506844C Novel peptides |
| 07/01/2009 | CN100506815C Piperidinyl targeting compounds that selectively bind integrins |
| 07/01/2009 | CN100506807C Amide derivatives as GK activators |
| 07/01/2009 | CN100506791C Pentafluorosulfanylbenzoylguanidines, preparation method, their use as medicaments or diagnostic aids, and medicaments comprising them |
| 07/01/2009 | CN100506776C NK1 antagonists |
| 07/01/2009 | CN100506311C Sustained delivery of an active agent using an implantable system |
| 07/01/2009 | CN100506277C Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 07/01/2009 | CN100506224C Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 06/30/2009 | USRE40811 Administering anti-VLA-4 antibody (or anti-VCAM-1 antibody) which blocks binding VLA-4 antigen on surface of CD34 cells to VCAM-1 or fibronectin, thereby increasing number of CD34+ cells in peripheral blood; colony stimulating factors |
| 06/30/2009 | US7553979 Heat Shock Protein 90 inhibitors; e.g. breast cancer, prostate cancer |
| 06/30/2009 | US7553971 Aryl aniline β2 adrenergic receptor agonists |
| 06/30/2009 | US7553939 Genes that encode cell surface molecules with conserved IgV and mucin domains; diagnosis or staging of cancer; treatment of an immunological disorder; detecting a predisposition to asthma |
| 06/30/2009 | US7553923 Medical devices and applications of polyhydroxyalkanoate polymers |
| 06/30/2009 | US7553918 pH-sensitive polymer |
| 06/30/2009 | US7553847 Treating obsessive-compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, somatization disorder; 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone |
| 06/30/2009 | US7553844 Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors |
| 06/30/2009 | US7553835 foam or mousse; antifungal such as ketoconazole, lower alcohol, fatty alcohol, a quaternary or ethoxylated sorbitan surfactant, water, hydrocarbon gas propellant; jock itch, tinea, dandruff and sebborheic dermatitis |
| 06/30/2009 | US7553821 Methods for selectively modulating survivin apoptosis pathways |
| 06/30/2009 | US7553817 Ribose; enhancing ATP recovery and synthesis; increasing exercise capacity |
| 06/30/2009 | US7553815 Therapeutic use |
| 06/30/2009 | US7553612 Cutting piece of living organ, digesting into discrete living animal cells and separating, suspending in a solution of sodium chloride containing sodium alginate and collagen, forming immunoisolation membranes around outer surface of microcapsules ofcells by covering with alginate-poly-L-lysine, freezing |
| 06/30/2009 | US7553493 Chlamydia flagellar protein antigen |
| 06/30/2009 | US7553483 Chemokine mutants acting as chemokine antagonists |
| 06/30/2009 | CA2527365C Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc |
| 06/30/2009 | CA2459399C Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole |
| 06/30/2009 | CA2368812C Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
| 06/30/2009 | CA2324970C Improved immunodiagnostic assays using reducing agents |
| 06/30/2009 | CA2295101C Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function |
| 06/25/2009 | WO2009076775A1 Immune response modulation and uses thereof |
| 06/25/2009 | WO2009023471A3 Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation |
| 06/25/2009 | WO2009020561A3 Compositions and methods of use thereof, for the treatment of oral pain, comprising cloves or extract thereof in combination with a steroid |
| 06/25/2009 | WO2009013480A3 Antibacterial combination therapy |
| 06/25/2009 | WO2008120219A3 Compositions and methods for cell killing |
| 06/25/2009 | WO2008089087A3 Tablet-in-tablet compositions |
| 06/25/2009 | WO2008076278A4 Methods of cancer treatment with igf1r inhibitors |
| 06/25/2009 | WO2007102861A3 Modulators of cdc2-like kinases (clks) and methods of use thereof |
| 06/25/2009 | US20090163591 Use of sugar phosphates, sugar phosphate analogs, amino acids and/or amino acid analogs for modulating the glucolysis-enzyme complex, the malate asparate shuttle and/or the transaminases |
| 06/25/2009 | US20090163530 adapted to adhere to and dissolve in a mouth of a consumer include a water soluble film-forming polymer pullulan, antimicrobially effective amounts of essential oils thymol, methyl salicylate, eucalyptol and menthol; for killing plaque-producing germs that cause dental plaque, bad breath, gingivitis |
| 06/25/2009 | US20090163523 Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
| 06/25/2009 | US20090163479 Use of taurolidine to treat tumors |
| 06/25/2009 | US20090163427 Pharmaceutical Composition of Enterosorbent and Prebiotics, Dosage Forms, and the Method for Prevention and Treatment of Gastrointestinal Disorders |
| 06/25/2009 | US20090163423 Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility |
| 06/25/2009 | US20090162867 Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| 06/25/2009 | US20090162381 Method for Treating Vascular Disorders |
| 06/25/2009 | US20090162331 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants |
| 06/25/2009 | US20090162330 Method of Isolating Human Neuroepithelial Precursor Cells from Human Fetal Tissue |
| 06/25/2009 | US20090162326 Method for isolating stem cells and stem cells derived from a pad-like tissue of teeth |
| 06/25/2009 | US20090162323 Method for Stimulating the Intestinal Flora |
| 06/25/2009 | US20090162286 Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions |
| 06/25/2009 | DE102007063535A1 Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose A pharmaceutical composition for prophylaxis and / or symptomatic treatment of cystic fibrosis |
| 06/25/2009 | DE102007063210A1 Arzneimittel zur Behandlung von Phantomphänomenen Drugs for treatment of phantom phenomena |
| 06/25/2009 | DE102007062411A1 Arzneimittel zur Behandlung von fibrosierenden Lungenkrankheiten Medicines to treat fibrotic lung diseases |
| 06/24/2009 | EP2072623A1 Screening method for prokinetic agent |
| 06/24/2009 | EP2072047A1 Therapeutic agent for opthalmic disease |
| 06/24/2009 | EP1660131B1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 06/24/2009 | EP1651246A4 Method for promoting bone growth |
| 06/24/2009 | EP1385522B1 Combination comprising a signal transduction inhibitor and an epothilone derivative |
| 06/24/2009 | EP1303591B1 Masp-2, a complement-fixing enzyme, and uses for it |
| 06/24/2009 | EP1152761B1 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| 06/24/2009 | EP1131106B1 Compositions and methods for producing vascular occlusion |
| 06/24/2009 | CN101461804A (+)-1-(3,4-dichlorrophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof |
| 06/24/2009 | CN100503605C Benzimidazole derivative and its use as AII receptor antagonist |
| 06/24/2009 | CN100503599C Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| 06/24/2009 | CN100503589C Sulphona mide derivatives as prodrugs of aspartyl protease inhibitors |
| 06/24/2009 | CN100503570C Cyanoguanidine prodrugs |
| 06/24/2009 | CN100502947C Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha |
| 06/24/2009 | CN100502946C Compound preparation for anti-pregnancy by killing sperm and sterilizing, and preparing method |
| 06/24/2009 | CN100502889C Oral and dental composition |
| 06/24/2009 | CN100502884C Re-epithelializing pharmaceutical compositions comprising xanthan gum |
| 06/24/2009 | CN100502874C Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 06/24/2009 | CN100502847C Compositions containing substituted quinolines and substituted diphenyl sulfones and its pharmaceutical use |
| 06/23/2009 | USRE40792 treating CANCER, PMS, MENOPAUSE AND HYPERCHOLESTEROLEMIA with plant extract of soya or clover and isoflavones from Genistein, Daidzein, Biochanin A, Formononetin or the natural glycosides; dosage forms |
| 06/23/2009 | US7550470 Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| 06/23/2009 | US7550469 Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands |
| 06/23/2009 | US7550451 Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy |
| 06/23/2009 | US7550437 administering a protein agonist for protease-activated receptor (PAR-2); side effects reduction; peptidase inhibitors (amistatins); drug delivery; biodrugs as antisecretory agents |
| 06/23/2009 | US7550426 Acetylated therapeutic procytotoxins |
| 06/23/2009 | US7550283 Bacteriophage for lysis of Methylobacterium and compositions and uses thereof |
| 06/23/2009 | US7550257 Hyperpolarizing with potential-sensitive fluorescent dye and isoosmolar sodium-ion-free buffer, incubating, determining membrane potential, adding sodium, recording change in potential; voltage sensitive oxonol dyes; sodium channel modulators; high throughput screening; fluorescent imaging plate reader |
| 06/23/2009 | US7550155 two excipients are: a block co-polymer (for example, a poloxamer ), and a polyethylene glycol (PEG); with this synergistic mixture it is possible to dissolve or suspend higher amounts of propofol and other lipophilic compounds while, at the same time, using smaller amounts of these excipients |
| 06/23/2009 | US7550145 Adjuvant compositions |
| 06/23/2009 | US7550142 Anti-integrin antibodies, compositions, methods and uses |
| 06/23/2009 | CA2492804C Novel inhibitors of kinases |
| 06/23/2009 | CA2459483C Plaster for the treatment of dysfunctions and disorders of nail growth |
| 06/23/2009 | CA2415042C Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure |
| 06/23/2009 | CA2389219C Dry powder compositions having improved dispersivity |
| 06/23/2009 | CA2373852C Oligosaccharide aldonic acids and their topical use |
| 06/23/2009 | CA2373611C Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| 06/23/2009 | CA2320628C Chelated 8-hydroxyquinoline for the treatment of epithelial lesions |
| 06/23/2009 | CA2304820C Stabilized bioactive preparations and methods of use |
| 06/23/2009 | CA2300148C Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| 06/23/2009 | CA2208078C Formulations and methods for reducing skin irritation |